Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of life (QoL). Current standard treatment, pancreatic enzyme replacement therapy (PERT), is limited by suboptimal adherence, high cost, and partial effectiveness to prevent fat malabsorption. The objective of the study is to assess the feasibility and maintenance of lipid absorption function of a structured lipid medical food (SLMF; Encala®) powder in subjects with PDAC and NET with EPI.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Feasibility of Encala Intervention ( Enrollment Rate )
Timeframe: From enrollment to end of intervention at 8 weeks
Change in PROMIS Gastrointestinal Symptom Score
Timeframe: Baseline to Week 8
Feasibility of Encala Intervention ( Retention Rate )
Timeframe: Baseline to Week 8
Feasibility of Encala Intervention ( Visit Completion)
Timeframe: Baseline to Visit 8
Feasibility of Encala Intervention ( Product Adherence )
Timeframe: Baseline to Visit 8